After Stifel Nicolaus and Needham gave Selecta Biosciences (NASDAQ: SELB) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Selecta Biosciences today and set a price target of $4.00. The company’s shares closed last Monday at $1.39, close to its 52-week low of $1.28.
According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -4.2% and a 34.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Xeris Pharmaceuticals, and Revance Therapeutics.
Selecta Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $6.33, which is a 295.6% upside from current levels. In a report issued on November 8, Needham also maintained a Buy rating on the stock with a $9.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.33 and a one-year low of $1.28. Currently, Selecta Biosciences has an average volume of 132.2K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SELB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.
